ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

OUTLINE: This is a dose-escalation study of ST-067 in combination with teclistamab followed by a dose-expansion study. Patients receive ST-067 subcutaneously (SC) on days 1, 8, 15 and 22 of cycle 1, on days 8, 15 and 22 of cycle 2, then on days 1 and 15 of subsequent cycles. Patients also receive teclistamab SC on days 1, 3, 5, 15 and 22 of cycle 2 then on days 1, 8, 15, and 22 or on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection throughout the trial and bone marrow aspiration and biopsy during screening and on study. After completion of study treatment, patients are followed every 3 months for up to 5 years.